Publication: In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort: A major human metabolite of deflazacort

This research article, published in Pharmacology Research & Perspectives, evaluates cytochrome P450 (CYP)- and transporter-mediated drug interaction potentials of 6β-hydroxy-21-desacetyl deflazacort (6β-OH-21-desDFZ)

Learn more about the pharmacokinetic drug interaction potential of 6 β-OH-21-desDFZ, a major circulating but not biologically active metabolite of deflazacort (DFZ)
The in vitro CYP- and transporter-mediated drug interaction potentials of 6β-OH-21-desDFZ is systematically evaluated
A novel approach to preparing radioactively labeled 14C-6β-OH-21-desDFZ using microbial biotransformation for transporter substrate assay is also presented

Ma J, Beers B, Manohar R, et al. Pharmacol Res Perspect. 2021;9:e00748

Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.

For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at usmedinfo@ptcbio.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.

Register now to unlock the content

Already registered?
If not, register below

Registration

Firstname *

Surname *

Hospital *

Work email *

Specialty *

Country *

This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

*

I confirm that I am a licensed healthcare professional and would like to access this Website

*

I understand that PTC will process my personal data, including contact details, for the purposes of providing me access to this Website

I want PTC to provide, by email, updates about new content available to view on MEDhub
PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

Publication: In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort: A major human metabolite of deflazacort

Authenticating...

COMING SOON